Symbols / SANA
SANA Chart
About
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.13B |
| Enterprise Value | 1.06B | Income | -234.41M | Sales | — |
| Book/sh | 0.74 | Cash/sh | 0.57 | Dividend Yield | — |
| Payout | 0.00% | Employees | 194 | IPO | — |
| P/E | — | Forward P/E | -7.47 | PEG | — |
| P/S | — | P/B | 5.68 | P/C | — |
| EV/EBITDA | -6.02 | EV/Sales | — | Quick Ratio | 4.31 |
| Current Ratio | 4.55 | Debt/Eq | 45.95 | LT Debt/Eq | — |
| EPS (ttm) | -0.96 | EPS next Y | -0.57 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-16 | ROA | -23.90% |
| ROE | -96.11% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 266.37M |
| Shs Float | 176.96M | Short Float | 37.76% | Short Ratio | 14.61 |
| Short Interest | — | 52W High | 6.55 | 52W Low | 1.26 |
| Beta | 1.97 | Avg Volume | 3.52M | Volume | 1.35M |
| Target Price | $8.71 | Recom | Strong_buy | Prev Close | $4.07 |
| Price | $4.23 | Change | 3.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.71
Mean price target
2. Current target
$4.23
Latest analyst target
3. DCF / Fair value
$-6.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.23
Low
$6.00
High
$12.00
Mean
$8.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-06 | main | B of A Securities | Buy → Buy | $7 |
| 2025-11-07 | main | Wedbush | Outperform → Outperform | $6 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-10-30 | main | Citizens | Market Outperform → Market Outperform | $8 |
| 2025-09-24 | init | Wedbush | — → Outperform | $5 |
| 2025-06-24 | reit | JMP Securities | Market Outperform → Market Outperform | $5 |
| 2025-04-24 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-18 | up | Citizens Capital Markets | Market Perform → Market Outperform | $5 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-14 | init | Jefferies | — → Buy | $7 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-01-08 | up | TD Cowen | Hold → Buy | — |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-05 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-05 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2024-08-09 | main | Citigroup | Buy → Buy | $15 |
| 2024-08-09 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-01 | main | JMP Securities | Market Outperform → Market Outperform | $15 |
- Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum - simplywall.st ue, 24 Feb 2026 04
- Commit To Purchase Sana Biotechnology At $2.50, Earn 26% Using Options - Nasdaq Wed, 04 Feb 2026 08
- Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet - Yahoo Finance Fri, 23 Jan 2026 08
- Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’ - Stocktwits Wed, 15 Oct 2025 07
- Sana Biotechnology stock falls after naming new CFO - Investing.com ue, 17 Feb 2026 15
- Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a Potential 86.60% Upside in the Biotech Arena - DirectorsTalk Interviews Fri, 16 Jan 2026 08
- Sana Biotechnology Names Brian Piper as New CFO - The Globe and Mail Wed, 18 Feb 2026 08
- Sana Biotech surges after Eric Jackson post (SANA:NASDAQ) - Seeking Alpha Wed, 15 Oct 2025 07
- Cell Therapy Pioneer Sana Biotechnology Headlines Four Major Healthcare Conferences in September 2025 - Stock Titan ue, 26 Aug 2025 07
- Can Sana Biotechnology’s (SANA) Pipeline Momentum Translate into More Share Price Upside? - Yahoo Finance Wed, 17 Sep 2025 07
- Sana Biotechnology stock tumbles after pricing public offering - Investing.com hu, 07 Aug 2025 07
- Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips (NASDAQ:SANA) - Seeking Alpha Mon, 19 Jan 2026 08
- Sana (SANA) Surges 14.5% Ahead of Business Announcements - Yahoo Finance Fri, 28 Nov 2025 08
- Sana Biotechnology stock higher after Eric Jackson touts 100-bagger potential - Investing.com Nigeria Wed, 15 Oct 2025 07
- Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains - Yahoo Finance Sun, 30 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6157 | — | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2026-01-05 00:00:00 | D |
| 1 | 7500 | nan | — | — | WYRICK SUSAN D | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 3400 | nan | — | — | WYRICK SUSAN D | Chief Financial Officer | — | 2025-12-12 00:00:00 | D |
| 3 | 20000 | nan | — | — | WYRICK SUSAN D | Chief Financial Officer | — | 2025-12-03 00:00:00 | D |
| 4 | 5628 | — | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2025-10-06 00:00:00 | D |
| 5 | 7842 | — | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2025-07-07 00:00:00 | D |
| 6 | 16339 | — | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2025-04-07 00:00:00 | D |
| 7 | 11041 | nan | — | — | CASSIDY BERNARD J | General Counsel | — | 2025-03-07 00:00:00 | D |
| 8 | 3250 | nan | — | — | WYRICK SUSAN D | Chief Financial Officer | — | 2025-03-07 00:00:00 | D |
| 9 | 50000 | nan | — | — | HARR STEVEN D | Chief Executive Officer | — | 2025-03-07 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -255.33M | -268.58M | -256.94M | -345.84M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -266.76M | -283.25M | -269.48M | -355.93M |
| ReconciledDepreciation | 17.39M | 24.56M | 15.62M | 11.07M |
| EBITDA | -255.33M | -268.58M | -256.94M | -345.84M |
| EBIT | -272.72M | -293.14M | -272.56M | -356.91M |
| NetInterestIncome | 10.47M | 9.94M | 3.76M | 676.00K |
| InterestIncome | 10.47M | 9.94M | 3.76M | 676.00K |
| NormalizedIncome | -266.76M | -283.25M | -269.48M | -355.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -266.76M | -283.25M | -269.48M | -355.93M |
| TotalExpenses | 272.72M | 293.14M | 272.56M | 356.91M |
| TotalOperatingIncomeAsReported | -272.72M | -293.14M | -272.56M | -356.91M |
| DilutedAverageShares | 230.89M | 194.54M | 188.34M | 166.43M |
| BasicAverageShares | 230.89M | 194.54M | 188.34M | 166.43M |
| DilutedEPS | -1.16 | -1.46 | -1.43 | -2.14 |
| BasicEPS | -1.16 | -1.46 | -1.43 | -2.14 |
| DilutedNIAvailtoComStockholders | -266.76M | -283.25M | -269.48M | -355.93M |
| NetIncomeCommonStockholders | -266.76M | -283.25M | -269.48M | -355.93M |
| NetIncome | -266.76M | -283.25M | -269.48M | -355.93M |
| NetIncomeIncludingNoncontrollingInterests | -266.76M | -283.25M | -269.48M | -355.93M |
| NetIncomeContinuousOperations | -266.76M | -283.25M | -269.48M | -355.93M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -266.76M | -283.25M | -269.48M | -355.93M |
| OtherIncomeExpense | -4.51M | -52.00K | -674.00K | 305.00K |
| OtherNonOperatingIncomeExpenses | -4.51M | -52.00K | -674.00K | 305.00K |
| NetNonOperatingInterestIncomeExpense | 10.47M | 9.94M | 3.76M | 676.00K |
| InterestIncomeNonOperating | 10.47M | 9.94M | 3.76M | 676.00K |
| OperatingIncome | -272.72M | -293.14M | -272.56M | -356.91M |
| OperatingExpense | 272.72M | 293.14M | 272.56M | 356.91M |
| ResearchAndDevelopment | 208.68M | 219.84M | 201.00M | 306.50M |
| SellingGeneralAndAdministration | 64.04M | 73.30M | 71.56M | 50.41M |
| GeneralAndAdministrativeExpense | 64.04M | 73.30M | 71.56M | 50.41M |
| OtherGandA | 64.04M | 73.30M | 71.56M | 50.41M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 223.92M | 197.86M | 191.02M | 184.93M |
| ShareIssued | 223.92M | 197.86M | 191.02M | 184.93M |
| TotalDebt | 94.20M | 104.10M | 108.25M | 110.94M |
| TangibleBookValue | 50.68M | 87.68M | 299.49M | 528.68M |
| InvestedCapital | 250.50M | 287.51M | 499.31M | 728.50M |
| WorkingCapital | 115.38M | 149.03M | 332.93M | 458.87M |
| NetTangibleAssets | 50.68M | 87.68M | 299.49M | 528.68M |
| CapitalLeaseObligations | 94.20M | 104.10M | 108.25M | 110.94M |
| CommonStockEquity | 250.50M | 287.51M | 499.31M | 728.50M |
| TotalCapitalization | 250.50M | 287.51M | 499.31M | 728.50M |
| TotalEquityGrossMinorityInterest | 250.50M | 287.51M | 499.31M | 728.50M |
| StockholdersEquity | 250.50M | 287.51M | 499.31M | 728.50M |
| GainsLossesNotAffectingRetainedEarnings | 14.00K | -60.00K | -4.33M | -1.37M |
| OtherEquityAdjustments | 14.00K | -60.00K | -4.33M | -1.37M |
| RetainedEarnings | -1.60B | -1.34B | -1.05B | -785.36M |
| AdditionalPaidInCapital | 1.86B | 1.63B | 1.56B | 1.52B |
| CapitalStock | 22.00K | 20.00K | 19.00K | 18.00K |
| CommonStock | 22.00K | 20.00K | 19.00K | 18.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 250.52M | 277.79M | 323.40M | 400.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 205.08M | 213.31M | 211.90M | 301.67M |
| OtherNonCurrentLiabilities | 123.42M | 122.41M | 116.04M | 199.89M |
| LongTermDebtAndCapitalLeaseObligation | 81.66M | 90.90M | 95.86M | 101.78M |
| LongTermCapitalLeaseObligation | 81.66M | 90.90M | 95.86M | 101.78M |
| CurrentLiabilities | 45.43M | 64.49M | 111.50M | 99.23M |
| OtherCurrentLiabilities | 55.34M | 56.38M | ||
| CurrentDebtAndCapitalLeaseObligation | 12.53M | 13.20M | 12.39M | 9.16M |
| CurrentCapitalLeaseObligation | 12.53M | 13.20M | 12.39M | 9.16M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.43M | 19.79M | 21.25M | 18.24M |
| PayablesAndAccruedExpenses | 21.47M | 31.51M | 22.52M | 15.45M |
| CurrentAccruedExpenses | 16.26M | 27.40M | 19.66M | 13.23M |
| Payables | 5.21M | 4.11M | 2.86M | 2.22M |
| AccountsPayable | 5.21M | 4.11M | 2.86M | 2.22M |
| TotalAssets | 501.02M | 565.30M | 822.72M | 1.13B |
| TotalNonCurrentAssets | 340.21M | 351.78M | 378.28M | 571.31M |
| OtherNonCurrentAssets | 5.12M | 6.37M | 9.01M | 13.82M |
| InvestmentsAndAdvances | 0.00 | 10.05M | 195.88M | |
| InvestmentinFinancialAssets | 0.00 | 10.05M | 195.88M | |
| AvailableForSaleSecurities | 10.05M | 195.88M | ||
| GoodwillAndOtherIntangibleAssets | 199.82M | 199.82M | 199.82M | 199.82M |
| OtherIntangibleAssets | 59.20M | 59.20M | 59.20M | 59.20M |
| Goodwill | 140.63M | 140.63M | 140.63M | 140.63M |
| NetPPE | 135.27M | 145.59M | 159.40M | 161.78M |
| AccumulatedDepreciation | -54.17M | -41.77M | -33.98M | -18.77M |
| GrossPPE | 189.44M | 187.36M | 193.38M | 180.56M |
| Leases | 33.34M | 31.36M | 34.43M | 33.85M |
| ConstructionInProgress | 40.34M | 26.33M | 1.71M | 1.39M |
| OtherProperties | 110.92M | 126.55M | 154.33M | 144.00M |
| MachineryFurnitureEquipment | 4.84M | 3.12M | 2.91M | 1.32M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 160.81M | 213.51M | 444.44M | 558.10M |
| OtherCurrentAssets | 4.48M | 4.49M | 14.37M | 7.11M |
| RestrictedCash | 3.83M | 3.83M | 6.10M | 0.00 |
| PrepaidAssets | 7.11M | |||
| CashCashEquivalentsAndShortTermInvestments | 152.50M | 205.19M | 423.96M | 551.00M |
| OtherShortTermInvestments | 24.93M | 71.68M | 247.20M | 297.97M |
| CashAndCashEquivalents | 127.57M | 133.52M | 176.76M | 253.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -256.58M | -273.61M | -310.93M | -280.92M |
| IssuanceOfDebt | 7.74M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 181.00M | 27.02M | 601.00K | 631.75M |
| CapitalExpenditure | -33.43M | -20.03M | -20.88M | -29.86M |
| EndCashPosition | 131.40M | 137.35M | 187.27M | 261.85M |
| BeginningCashPosition | 137.35M | 187.27M | 261.85M | 126.95M |
| ChangesInCash | -5.95M | -49.92M | -74.58M | 134.90M |
| FinancingCashFlow | 199.75M | 31.65M | 4.91M | 631.75M |
| CashFlowFromContinuingFinancingActivities | 199.75M | 31.65M | 4.91M | 631.75M |
| ProceedsFromStockOptionExercised | 11.01M | 4.63M | 4.31M | 5.35M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 181.00M | 27.02M | 601.00K | 631.75M |
| CommonStockIssuance | 181.00M | 27.02M | 601.00K | 631.75M |
| NetIssuancePaymentsOfDebt | 7.74M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | 7.74M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 7.74M | 0.00 | 0.00 | |
| InvestingCashFlow | 17.45M | 172.01M | 210.56M | -245.80M |
| CashFlowFromContinuingInvestingActivities | 17.45M | 172.01M | 210.56M | -245.80M |
| NetOtherInvestingChanges | -4.57M | |||
| NetInvestmentPurchaseAndSale | 50.88M | 192.04M | 231.44M | -211.36M |
| SaleOfInvestment | 276.95M | 349.79M | 310.13M | 280.02M |
| PurchaseOfInvestment | -226.06M | -157.74M | -78.69M | -491.39M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -33.43M | -20.03M | -20.88M | -29.86M |
| PurchaseOfPPE | -33.43M | -20.03M | -20.88M | -29.86M |
| OperatingCashFlow | -223.15M | -253.58M | -290.05M | -251.05M |
| CashFlowFromContinuingOperatingActivities | -223.15M | -253.58M | -290.05M | -251.05M |
| ChangeInWorkingCapital | -1.19M | 18.61M | 7.54M | 9.80M |
| ChangeInOtherWorkingCapital | 9.34M | 10.96M | 1.56M | 5.09M |
| ChangeInPayablesAndAccruedExpense | -7.01M | -491.00K | 11.97M | 5.57M |
| ChangeInAccruedExpense | -8.39M | -1.52M | 10.91M | 5.84M |
| ChangeInPayable | 1.38M | 1.03M | 1.06M | -266.00K |
| ChangeInAccountPayable | 1.38M | 1.03M | 1.06M | -266.00K |
| ChangeInPrepaidAssets | -3.51M | 8.14M | -5.99M | -861.00K |
| OtherNonCashItems | -10.28M | -49.03M | -82.08M | 61.64M |
| StockBasedCompensation | 37.68M | 35.53M | 38.34M | 22.36M |
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 17.39M | 24.56M | 15.62M | 11.07M |
| DepreciationAndAmortization | 17.39M | 24.56M | 15.62M | 11.07M |
| Depreciation | 17.39M | 24.56M | 15.62M | 11.07M |
| NetIncomeFromContinuingOperations | -266.76M | -283.25M | -269.48M | -355.93M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SANA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|